The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 37, No. 4, pp. 582-585. DOI 10.1345/aph.1C345
© 2003 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clay, P. G
Right arrow Articles by Lam, A. I
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clay, P. G
Right arrow Articles by Lam, A. I

DRUG INFORMATION ROUNDS

Testosterone Replacement Therapy for Bone Loss Prevention in HIV-Infected Males

Patrick G Clay, PharmD

Assistant Professor, Division of Pharmacy Practice, School of Pharmacy, University of Missouri at Kansas City, Kansas City, MO; HIV Clinical Specialist, Kansas City Free Health Clinic, Kansas City

Amy I Lam

PharmD Student, School of Pharmacy, University of Missouri at Kansas City

Reprints: Patrick G Clay PharmD, Division of Pharmacy Practice, School of Pharmacy, University of Missouri at Kansas City, M3-C19, 2411 Holmes St., Kansas City, MO 64108-2792, FAX 816/753-0804, E-mail claypg{at}umkc.edu

OBJECTIVE: To review the use of testosterone for the prevention of bone loss in men with HIV infection.

DATA SOURCES: A MEDLINE search (1966–May 2002) on the use of testosterone in osteoporosis/HIV infection was performed. A reference bibliography search was also completed.

DATA SYNTHESIS: Osteopenia/osteoporosis is reported in HIV-infected men due to a myriad of factors. Sex hormone deficiency is a frequent endocrine abnormality in this population.

CONCLUSIONS: In HIV-negative men, testosterone may be beneficial for preventing bone loss and hastening the resolution of fractures. Testosterone's role in preventing bone loss in HIV-infected men remains to be defined.

Key Words: AIDS, HIV, osteopenia, osteoporosis, testosterone

Published Online, March 6, 2003. www.theannals.com, DOI 10.1345/aph.1C345


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
P. G Clay, L. E Voss, C. Williams, and E. C Daume
Valid Treatment Options for Osteoporosis and Osteopenia in HIV-Infected Persons
Ann. Pharmacother., May 1, 2008; 42(5): 670 - 679.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2003 by Harvey Whitney Books Company.